Royalty Report: Drugs, Disease, Pharmaceuticals – Collection: 256221

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Drugs
  • Disease
  • Pharmaceuticals
  • Drug Discovery
  • Autoimmune
  • Kidneys
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 256221

License Grant
Licensor grants the Licensee of Sweden
–   an exclusive, including with regard to Licensor and its Affiliates, right and license under the Licensed Technology and Licensors rights in the Joint Technology to Exploit the Licensed Compounds and Licensed Products solely for the purpose of Developing, Manufacturing and Commercializing Licensed Products in the Field and in the Territory.
–  an exclusive, including with regard to Licensor and its Affiliates, right and license under the Licensor Acquired Technology to Develop, Manufacture and Commercialize the Licensed Compounds and Licensed Products in the Field and in the Territory.
–  an exclusive, including with regard to Licensor and its Affiliates, right and license and right of reference in the Territory under Licensor s and its Affiliates rights, titles and interests in and to the Regulatory Approvals, to Develop, Manufacture and Commercialize the Licensed Compounds and Licensed Products in the Field and in the Territory.

This agreement contains a non-exclusive grant-back from Licensee to Licensor.

License Property
The Licensor has certain proprietary compounds known as NHE3 inhibitors for use in the treatment of human diseases and disorders, and has filed an Investigational New Drug application for one of such compounds, designated as RDX5791.

The Lead Licensed Compound means the NHE3 inhibitor designated as RDX5791, which is the subject of the IBS-C IND and the Cardio/Renal IND, and any metabolites, salts, esters, free acid forms, crystal forms, free base forms, pro-drug forms, racemates and all optically active forms thereof.

The patents include Patent Family I regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders;Patent Family II regarding Methods For Diverting Sodium From Systemic Circulation;  Patent Family Ill regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders (Indanes);  and, Patent Family IV regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in theTreatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders (Multimers).

NHE3 inhibitor programme includes the Phase 2-ready lead compound RDX5791, for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). NHE3 is the sodium–hydrogen antiporter 3, a protein essential in the absorption of sodium in the intestines.

Field of Use
On this basis, the Parties plan to develop RDX5791 for use in ESRD and CKD in addition to IBS-C, and intend to evaluate possible development in other diseases that are a consequence of sodium and fluid overload.

End-Stage Renal Disease (ESRD) is a medical condition in which a person's kidneys cease functioning on a permanent basis leading to the need for a regular course of long-term dialysis or a kidney transplant to maintain life.
Chronic kidney disease (CKD) means your kidneys are damaged and can't filter blood the way they should. The main risk factors for developing kidney disease are diabetes, high blood pressure, heart disease, and a family history of kidney failure.
IBS-C is a type of IBS in which the abdominal discomfort or bloating happens with constipation. Generally, constipation is when stools don't pass often enough (less than three times per week).

IPSCIO Record ID: 29751

License Grant
Under the License Agreement dated as of October 4, 2012, as amended  December 23, 2013, the Licensor granted the Licensee a worldwide, exclusive License to its proprietary compounds known as NHE3 inhibitors.

This Agreement is being terminated.

License Property
The Licensor shall provide Licensee with a list of and a copy of each agreement, in order to enable Licensee to determine the agreements, if any, with respect to which it will request assignment.

NHE3 inhibitor programme include the Phase 2-ready lead compound RDX5791, for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). NHE3 is the sodium–hydrogen antiporter 3, a protein essential in the absorption of sodium in the intestines.

Field of Use
The Licensor has determined that it no longer desires to continue its activities under the License Agreement.

IPSCIO Record ID: 256223

License Grant
With this Exclusive License to Complete Pre-Clinical Development Plan, The Licensor grants the Licensee of France
–  a worldwide, exclusive, including with regard to Licensor and its Affiliates, right and license under both the Licensed Technology and Licensors rights in the Joint Technology to conduct research regarding Program Compounds solely for the purpose of completing the PreClinical Development Plan, with the right to grant sublicenses solely to Affiliates.

–  an exclusive License to Licensee Following the Exercise of the Option to Continue, a worldwide exclusive, including with regard to Licensor and its Affiliates, right and license under the Licensed Technology and Licensors rights in the Joint Technology to Exploit the Program Compounds solely for the purpose of Developing, Manufacturing and Commercializing Program Products in the Field and in the Territory, with the right to grant sublicenses.

Licensor grants an exclusive option, exercisable at any time during the Option Exercise Period, to Exploit Program Compounds and Program Products under the terms set forth in this Agreement.

This agreement includes a non-exclusive grant-back from Licensee to Licensor.

License Property
Licensor has certain proprietary compounds known as NaP2b inhibitors for use in the treatment of diseases and disorders, and has identified a lead compound, designated as NTX 1942.

The Lead Licensor Compound shall mean the NaP2b inhibitor, designated as NTX1942, and any metabolites, salts, esters, free acid forms, crystal forms, free base forms, pro-drug forms, racemates and all optically active forms thereof.

NaP2b shall mean the sodium phosphate co-transporter 2B encoded by the SCL34A2 gene, also sometimes identified in scientific literature as NaPi2b or NPT2b.

The licensed patents are Licensors NaP2b Patent Portfolio.

Field of Use
NaP2b program includes a portfolio of minimally-absorbed NaP2b inhibitors in discovery and preclinical stage of development, and Licensee will have full responsibility for further discovery efforts and development of any products. NaP2b is an intestinal phosphate transporter whose activity accounts for a significant portion of dietary phosphate absorption in humans. The inhibition of NaP2b should have utility for the treatment of hyperphosphatemia (elevated serum phosphate) in patients with end stage renal disease (ESRD) and other forms of chronic kidney disease (CKD).
Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood. Most people have no symptoms while others develop calcium deposits in the soft tissue. Often there is also low calcium levels which can result in muscle spasms.

IPSCIO Record ID: 227104

License Grant
The Licensor is providing the Licensee with the exclusive rights to develop and commercialize tenapanor in China for the treatment of patients with hyperphosphatemia related to CKD and patients with IBS-C.
License Property
Tenapanor is a first-in-class inhibitor of NHE3. In our renal pipeline, tenapanor is being evaluated in a second Phase 3 trial for the treatment of hyperphosphatemia in patients with ESRD who are on dialysis.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 304790

License Grant
Licensee of Sweden was granted (i) an exclusive license to certain patents and joint intellectual property developed with Licensor and (ii) a non-exclusive license to certain of Licensor know-how as necessary or useful to develop and commercialize Nefecon or other product candidates.
License Property
Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant. Nefecon is currently the only pharmaceutical candidate in development for IgAN that is intended to be disease-modifying. Nefecon targets the ileum, the distal region of the small intestine, which is the presumed origin of IgAN due to the ileum being the location of the highest concentration of the Peyer’s patches, which are responsible for the production of secretory immunoglobulin A, or IgA, antibodies. Nefecon has been granted orphan drug designation for the treatment of IgAN in the United States and the European Union.
Field of Use
The filed of use is for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN for which there is a high unmet medical need and there are no approved treatments. IgAN is a progressive, chronic disease that over time results in deterioration of kidney function in patients, many of whom end up at risk of developing end-stage renal disease, or ESRD, with the need for dialysis or kidney transplant.

IgA nephropathy (IgAN), also known as Berger's disease or synpharyngitic glomerulonephritis, is a disease of the kidney (or nephropathy) and the immune system; specifically it is a form of glomerulonephritis or an inflammation of the glomeruli of the kidney. Aggressive Berger's disease (a rarer form of the disease) can attack other major organs, such as the liver, skin and heart.

Licensee is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.  Licensee expects that Nefecon will be the first treatment on the market indicated for IgAN, and, that Nefecon can successfully treat IgAN patients, their kidney function will be preserved.

IPSCIO Record ID: 29157

License Grant
The Company announced that the Licensor decided not to exercise its option under the product development and commercialization Agreement between the Licensor and the Licensee to License XL784 for further development and commercialization. The Licensee announced in October 2007 that a phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy. As a result of the Licensor's decision, the Licensee has the right to develop and commercialize XL784 either independently or in collaboration with third parties, subject to royalty payments to on sales of any products incorporating the compound. The Company itself does not intend to invest further in the development of this drug, but will seek a partner with which to take the compound forward.
Field of Use
XL784 is a potent small molecule inhibitor of the ADAM-10 metalloprotease enzyme, which plays a role in blood vessel formation and cell proliferation that can cause renal fibrosis and impairment.  Diabetic nephropathy (nephropatia diabetica), also known as Kimmelstiel-Wilson syndrome and intercapillary glomerulonephritis, is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli. It is characterized by nephrotic syndrome and diffuse glomerulosclerosis. It is due to longstanding diabetes mellitus, and is a prime cause for dialysis in many Western countries.  Nephropathy means kidney disease or damage. Diabetic nephropathy is damage to your kidneys caused by diabetes. In severe cases it can lead to kidney failure.  The kidneys have many tiny blood vessels that filter waste from your blood. High blood sugar from diabetes can destroy these blood vessels. Over time, the kidney isn't able to do its job as well. Later it may stop working completely. This is called kidney failure.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.